ID   SW527
AC   CVCL_3799
SY   SW-527; SW 527
DR   CLO; CLO_0009219
DR   EFO; EFO_0005462
DR   ArrayExpress; E-MTAB-2706
DR   ATCC; CRL-7940
DR   BioSample; SAMN03151930
DR   BioSample; SAMN03481115
DR   cancercelllines; CVCL_3799
DR   Cosmic; 1047713
DR   DepMap; ACH-001825
DR   EGA; EGAS00001000610
DR   EGA; EGAS00001002554
DR   LINCS_HMS; 50046
DR   LINCS_LDP; LCL-1474
DR   PharmacoDB; SW527_1526_2019
DR   PRIDE; PXD008222
DR   Wikidata; Q54971177
RX   PubMed=288927;
RX   PubMed=327080;
RX   PubMed=833871;
RX   PubMed=20143388;
RX   PubMed=22585861;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=25892236;
RX   PubMed=26589293;
WW   http://dpsc.ccbr.utoronto.ca/cancer/get_cellline.pl?cellline=SW527
WW   https://iclac.org/wp-content/uploads/Cross-Contaminations_v12_distribution.xlsx
CC   Problematic cell line: Contaminated. Shown to be a SW480 derivative (PubMed=288927; PubMed=20143388). Originally thought to originate from a 70 year old female patient with a metastatic breast carcinoma.
CC   Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).
CC   Part of: Naval Biosciences Laboratory (NBL) collection (transferred to ATCC in 1982).
CC   From: Scott and White Clinic; Temple; USA.
CC   Registration: International Cell Line Authentication Committee, Register of Misidentified Cell Lines; ICLAC-00089.
CC   Population: Caucasian.
CC   HLA typing: A*02:01,24:02; B*07:02,15:18; C*07:04,07:04; DQA1*01:02,01:02; DQB1*05:01,05:01; DRB1*01:03,15:01 (PubMed=26589293).
CC   Sequence variation: Mutation; HGNC; 583; APC; Simple; p.Gln1338Ter (c.4012C>T); ClinVar=VCV000000801; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6407; KRAS; Simple; p.Gly12Val (c.35G>T); ClinVar=VCV000012583; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg273His (c.818G>A); ClinVar=VCV000012366; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Pro309Ser (c.925C>T); ClinVar=VCV000458575; Zygosity=Heterozygous (from parent cell line).
CC   Omics: Deep exome analysis.
CC   Omics: Deep quantitative proteome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by microarray.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Derived from site: In situ; Colon; UBERON=UBERON_0001155.
ST   Source(s): ATCC; DepMap; PubMed=25877200
ST   Amelogenin: X
ST   CSF1PO: 13,14
ST   D13S317: 12
ST   D16S539: 9,13
ST   D18S51: 13
ST   D21S11: 30,30.2
ST   D3S1358: 15,16
ST   D5S818: 13
ST   D7S820: 8
ST   D8S1179: 13
ST   FGA: 24
ST   Penta D: 9,15
ST   Penta E: 10
ST   TH01: 8
ST   TPOX: 11
ST   vWA: 16
DI   NCIt; C4349; Colon adenocarcinoma
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0546 ! SW480
SX   Male
AG   51Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 31
//
RX   PubMed=288927; DOI=10.1093/jnci/63.3.635;
RA   Leibovitz A., Wright W.C., Pathak S., Siciliano M.J., Daniels W.P.,
RA   Fogh H., Fogh J.;
RT   "Detection and analysis of a glucose 6-phosphate dehydrogenase
RT   phenotype B cell line contamination.";
RL   J. Natl. Cancer Inst. 63:635-645(1979).
//
RX   PubMed=327080; DOI=10.1093/jnci/59.1.221;
RA   Fogh J., Fogh J.M., Orfeo T.;
RT   "One hundred and twenty-seven cultured human tumor cell lines
RT   producing tumors in nude mice.";
RL   J. Natl. Cancer Inst. 59:221-226(1977).
//
RX   PubMed=833871; DOI=10.1093/jnci/58.2.209;
RA   Fogh J., Wright W.C., Loveless J.D.;
RT   "Absence of HeLa cell contamination in 169 cell lines derived from
RT   human tumors.";
RL   J. Natl. Cancer Inst. 58:209-214(1977).
//
RX   PubMed=20143388; DOI=10.1002/ijc.25242;
RA   Capes-Davis A., Theodosopoulos G., Atkin I., Drexler H.G., Kohara A.,
RA   MacLeod R.A.F., Masters J.R.W., Nakamura Y., Reid Y.A., Reddel R.R.,
RA   Freshney R.I.;
RT   "Check your cultures! A list of cross-contaminated or misidentified
RT   cell lines.";
RL   Int. J. Cancer 127:1-8(2010).
//
RX   PubMed=22585861; DOI=10.1158/2159-8290.CD-11-0224;
RA   Marcotte R., Brown K.R., Suarez Saiz F.J., Sayad A., Karamboulas K.,
RA   Krzyzanowski P.M., Sircoulomb F., Medrano M., Fedyshyn Y., Koh J.L.Y.,
RA   van Dyk D., Fedyshyn B., Luhova M., Brito G.C., Vizeacoumar F.J.,
RA   Vizeacoumar F.S., Datti A., Kasimer D., Buzina A., Mero P.,
RA   Misquitta C., Normand J., Haider M., Ketela T., Wrana J.L.,
RA   Rottapel R., Neel B.G., Moffat J.;
RT   "Essential gene profiles in breast, pancreatic, and ovarian cancer
RT   cells.";
RL   Cancer Discov. 2:172-189(2012).
//
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
//
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
//
RX   PubMed=25892236; DOI=10.1016/j.celrep.2015.03.050;
RA   Lawrence R.T., Perez E.M., Hernandez D., Miller C.P., Haas K.M.,
RA   Irie H.Y., Lee S.-I., Blau C.A., Villen J.;
RT   "The proteomic landscape of triple-negative breast cancer.";
RL   Cell Rep. 11:630-644(2015).
//
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
//